Section 646A.680 – Legislative intent.
The legislative intent of ORS 646A.683 is to improve public health and safety by taking steps to address the spiraling health care costs for residents of this state. [2019 c.436 §1]
Section 646A.683 – Requirement to report increase in drug price; exemptions.
(1) As used in this section: (a) “Drug” has the meaning given that term in ORS 689.005. (b)(A) “Manufacture” means: (i) The production, preparation, propagation, compounding, conversion or processing of a drug, either directly or indirectly by extraction from substances of natural origin or independently by means of chemical synthesis, or by a combination of […]
Section 646A.686 – Short title.
ORS 646A.689 and 646A.692 shall be known and may be cited as the Prescription Drug Price Transparency Act. [2018 c.7 §1]
Section 646A.689 – Requirement to report certain information concerning drug manufacturing and pricing; contents of report; penalty; rules.
(1) As used in this section and ORS 646A.693 to 646A.695: (a) “Drug” has the meaning given that term in ORS 689.005. (b) “Health care facility” has the meaning given that term in ORS 442.015. (c) “Health care service contractor” has the meaning given that term in ORS 750.005. (d)(A) “Manufacture” means: (i) The production, […]
Section 646A.692 – Civil penalty.
(1) A manufacturer that fails to report or provide information as required by ORS 646A.689 may be subject to a civil penalty as provided in this section. (2) The Department of Consumer and Business Services shall adopt a schedule of penalties, not to exceed $10,000 per day of violation, based on the severity of each […]